• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Scancell signs Commercial License Agreement with Genmab

by admin | Oct 25, 2022 | GlyMab, Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell Change of Registered Office

by admin | Sep 6, 2022 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

First patient dosed in Cohort 2 of the ModiFY Phase 1 clinical trial

by admin | Aug 16, 2022 | Latest News, Modi-1, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell to produce and clinically validate T cell redirecting bispecific antibodies

by admin | Jun 23, 2022 | GlyMab, Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Phase 2 SCOPE trial of SCIB1 vaccine in metastatic melanoma patients expanded

by admin | Jun 15, 2022 | Latest News, Regulatory News, SCIB1

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

First patient dosed in Modi-1 Phase 1 clinical trial

by admin | Jun 13, 2022 | Latest News, Modi-1, Moditope, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
« Older Entries
Next Entries »

Recent Posts

  • Active Immunotherapy: Ready For Prime Time
  • Strategic transactions to unlock longer-term value
  • Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
  • iSCIB1+ pivotal trial plans advancing
  • AACR (American Association for Cancer Research) Annual Meeting, April 2026, San Diego, California

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy